Verapamil Hydrochloride BP tablets in 40 mg and 80 mg strengths for prescribed cardiovascular indications. These product labels do not establish a sustained-release formulation.
40 mg: Verapamil Hydrochloride BP 40 mg; titanium dioxide and excipients q.s. as stated in supplied composition. Exact coating and release characteristics require confirmation.
80 mg: Each film-coated tablet contains Verapamil Hydrochloride BP 80 mg.
Therapeutic category: Non-dihydropyridine calcium-channel blocker / Cardiovascular medicine.
Manufacturer named: Healthy Life Pharma Pvt. Ltd. Exporter named: Healthy Inc. Certifications require documentary verification.
B2B enquiries: +91 7710003340
Verapamil Hydrochloride Tablets BP is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Verapamil hydrochloride is a non-dihydropyridine calcium-channel blocker used for selected cardiovascular conditions, including high blood pressure, angina and some supraventricular arrhythmias. The supplied product labels support a 40 mg verapamil hydrochloride BP tablet and an 80 mg film-coated verapamil hydrochloride BP tablet.
Although the general marketing brief mentions 120 mg and 240 mg sustained-release products, no matching product label was supplied for those strengths. Accordingly, this page does not represent either 40 mg or 80 mg as sustained-release.
Healthy Life Pharma Pvt. Ltd. is named as manufacturer and Healthy Inc as exporter in the supplied commercial text. Certifications require current verification.
| Product | Verapamil Hydrochloride Tablets BP |
|---|---|
| 40 mg composition | Verapamil Hydrochloride BP 40 mg; titanium dioxide and excipients q.s. as stated |
| 80 mg composition | Each film-coated tablet contains Verapamil Hydrochloride BP 80 mg |
| Confirmed strengths | 40 mg / 80 mg |
| Dosage form | 40 mg: tablet, coating unspecified; 80 mg: film-coated tablet |
| Standard | BP, as stated in supplied product text |
| Therapeutic class | Calcium-channel blocker / Antihypertensive / Antianginal |
| SR strengths in general description | 120 mg and 240 mg; not confirmed by supplied product labels |
| Packaging and shelf life | Subject to approved product registration and stability data |
Quality manufacturing of verapamil tablets involves verification of active-ingredient identity, blend uniformity, tablet compression, coating where specified, dissolution and stability. Film coating may assist swallowing and product protection.
Modified-release verapamil products require separately validated release-control technology and multipoint dissolution testing. The supplied 40 mg and 80 mg labels do not establish hydrophilic matrix technology or a 24-hour release profile.
Do not infer extended-release performance from tablet strength or film coating alone.
Verapamil blocks L-type calcium channels, relaxing arterial smooth muscle and slowing conduction through the heart's atrioventricular (AV) node.
Indications vary by local approval and formulation. Verapamil is not appropriate for every patient with heart failure or arrhythmia.
Potential B2B support may include CTD/ACTD dossiers, product specifications, certificates of analysis and registration documentation, subject to actual availability and destination-country requirements.
WHO-GMP, COPP, FSC, Star Export House status, packaging, shelf life and shipping terms must be verified before being represented as confirmed.
Q: Which verapamil strengths are confirmed?
A: 40 mg and 80 mg verapamil hydrochloride BP are stated in the supplied product compositions.
Q: Are both tablets film-coated?
A: The 80 mg label explicitly says film-coated. The 40 mg composition mentions titanium dioxide but does not clearly establish the coating type.
Q: Are these sustained-release tablets?
A: The supplied labels do not confirm sustained release for either strength. The 120 mg and 240 mg SR presentations in the general brief require separate verification.
Q: Can verapamil interact with other heart medicines?
A: Yes. Beta-blockers, digoxin and other medicines may increase cardiac or drug-interaction risks; a prescriber should review all treatment.
Dosage and frequency are individualized according to the approved formulation, indication, blood pressure, heart rate, other medicines and patient characteristics. Immediate-release and sustained-release verapamil must not be substituted without professional assessment.
Follow the exact registered label for administration. Never crush or chew a verified sustained-release product unless the product instructions specifically permit it.
Seek urgent care for fainting, very slow heartbeat, severe dizziness, breathing difficulty or worsening chest pain.
Store according to the temperature, light and moisture conditions stated on the approved product label, in original packaging. The supplied text does not independently establish a universal below-25°C limit or a 36-month shelf life. Keep out of reach of children.
For healthcare professional and B2B reference. Product availability, approvals, certifications, manufacturing processes, packaging and prescribing details must be verified for the relevant market.